Our official English website, www.x-mol.net, welcomes your
feedback! (Note: you will need to create a separate account there.)
Multivalent Aptamer-Based Lysosome-Targeting Chimeras (LYTACs) Platform for Mono- or Dual-Targeted Proteins Degradation on Cell Surface
Advanced Science ( IF 14.3 ) Pub Date : 2024-02-29 , DOI: 10.1002/advs.202308924
Qiao Duan 1 , Hao-Ran Jia 1, 2 , Weichang Chen 2 , Chunhong Qin 2 , Kejing Zhang 2, 3 , Fei Jia 2 , Ting Fu 2 , Yong Wei 2 , Mengyang Fan 2 , Qin Wu 2 , Weihong Tan 1, 2
Advanced Science ( IF 14.3 ) Pub Date : 2024-02-29 , DOI: 10.1002/advs.202308924
Qiao Duan 1 , Hao-Ran Jia 1, 2 , Weichang Chen 2 , Chunhong Qin 2 , Kejing Zhang 2, 3 , Fei Jia 2 , Ting Fu 2 , Yong Wei 2 , Mengyang Fan 2 , Qin Wu 2 , Weihong Tan 1, 2
Affiliation
![]() |
Selective protein degradation platforms have opened novel avenues in therapeutic development and biological inquiry. Antibody-based lysosome-targeting chimeras (LYTACs) have emerged as a promising technology that extends the scope of targeted protein degradation to extracellular targets. Aptamers offer an advantageous alternative owing to their potential for modification and manipulation toward a multivalent state. In this study, a chemically engineered platform of multivalent aptamer-based LYTACs (AptLYTACs) is established for the targeted degradation of either single or dual protein targets. Leveraging the biotin-streptavidin system as a molecular scaffold, this investigation reveals that trivalently mono-targeted AptLYTACs demonstrate optimum efficiency in degrading membrane proteins. The development of this multivalent AptLYTACs platform provides a principle of concept for mono-/dual-targets degradation, expanding the possibilities of targeted protein degradation.
中文翻译:
基于多价适体的溶酶体靶向嵌合体 (LYTAC) 平台,用于细胞表面的单或双靶向蛋白质降解
选择性蛋白质降解平台为治疗开发和生物学研究开辟了新途径。基于抗体的溶酶体靶向嵌合体(LYTAC)已成为一项有前途的技术,它将靶向蛋白质降解的范围扩展到细胞外靶点。适体提供了一种有利的替代方案,因为它们具有修饰和操纵多价状态的潜力。在这项研究中,建立了基于多价适体的 LYTAC(AptLYTAC)的化学工程平台,用于单或双蛋白质靶标的靶向降解。这项研究利用生物素-链霉亲和素系统作为分子支架,表明三价单靶向 AptLYTAC 在降解膜蛋白方面表现出最佳效率。这种多价 AptLYTACs 平台的开发为单/双靶点降解提供了概念原则,扩大了靶向蛋白质降解的可能性。
更新日期:2024-02-29
中文翻译:

基于多价适体的溶酶体靶向嵌合体 (LYTAC) 平台,用于细胞表面的单或双靶向蛋白质降解
选择性蛋白质降解平台为治疗开发和生物学研究开辟了新途径。基于抗体的溶酶体靶向嵌合体(LYTAC)已成为一项有前途的技术,它将靶向蛋白质降解的范围扩展到细胞外靶点。适体提供了一种有利的替代方案,因为它们具有修饰和操纵多价状态的潜力。在这项研究中,建立了基于多价适体的 LYTAC(AptLYTAC)的化学工程平台,用于单或双蛋白质靶标的靶向降解。这项研究利用生物素-链霉亲和素系统作为分子支架,表明三价单靶向 AptLYTAC 在降解膜蛋白方面表现出最佳效率。这种多价 AptLYTACs 平台的开发为单/双靶点降解提供了概念原则,扩大了靶向蛋白质降解的可能性。